Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eleanor Malone

London, UK
Eleanor has been editor of Scrip Intelligence since 2014. She has more than 15 years’ experience writing specialist news and analysis for and about the biopharma industry. She holds an MA in modern languages from the University of Edinburgh. Based in London, she appears regularly on TV and radio and conference panels to discuss matters related to the industry.
Advertisement
Set Alert for Articles By Eleanor Malone

Latest From Eleanor Malone

Learning From Human Cell Hijacking Masters: ENYO Pharma Takes Virus Tricks Into Drug Discovery

Emerging Company Profile: ENYO Pharma has been around for barely four years, but it is already advancing its lead programs into Phase II trials in hepatitis B and NASH, and anticipates many more uses for its virology-based platform that will go way beyond treating virus infections.

StartUps and SMEs Platform Technologies

Deal Watch: BridgeBio To Launch New Subsidiary Around Rare Disease Candidate Obtained From Alexion

Sanofi completes the transition of its infectious disease unit to Evotec. Perhaps not yet done with virology, Gilead licenses technology for HIV/hep B vaccines from Hookipa.

Deals Business Strategies

HVIVO Seeks Big Pharma Partner For ‘Phase III-Ready’ Universal Flu Vaccine

Presenting Phase IIb data on FLU-v, specialized CRO hVIVO now hopes to secure a big pharma partner for Phase III studies and commercialization of the universal flu vaccine candidate. The product has been developed in a joint venture with SEEK.

Vaccines Clinical Trials

Lilly/AstraZeneca's Lanabecestat Becomes Latest BACE Inhibitor Casualty

Just weeks after Johnson & Johnson halted development of its BACE inhibitor for Alzheimer's and a few months after Merck & Co failed at Phase III, Lilly and AstraZeneca end trials of lanabecestat.

Neurology Clinical Trials

Academic Study Confounds Latest UK Zytiga Reimbursement Consultation

Janssen, the Institute of Cancer Research and patient groups have reacted with disappointment to NICE draft guidance recommending that Zytiga should not be funded by England's National Health Service in a subset of prostate cancer patients. But the existence of an academic study has complicated the situation in an unusual way, and Janssen still hopes to steer a path to reimbursement.

Health Technology Assessment Reimbursement

Janssen Exec On Speeding Earlier Myeloma Interventions To Market With Key Biomarker

Having scored a commercial hit with Darzalex in myeloma, Janssen is looking to speed label expansions to the drug to enable it to intercept earlier in the disease. Janssen R&D executive Craig Tendler explained the importance of addressing smoldering myeloma and of recognizing minimal residual disease as a valid surrogate marker in trials.

Clinical Trials Drug Review
See All
Advertisement
UsernamePublicRestriction

Register